海南医科大学学报2025，Vol.31Issue(18)：1361-1369,9.DOI:10.13210/j.cnki.jhmu.20241230.001
黎药胆木治疗糖尿病肾病的网络药理学研究及实验验证
Network pharmacology research and experimental verification of Li Medicine Nauclea officinalis in the treatment of diabetic nephropathy
摘要
Abstract
Objective:To study the potential mechanism of the active ingredients of Liyao Nauclea(N.)officinalis in the treat-ment of diabetic nephropathy by using network pharmacology and in vitro experiments.Methods:Through CNKI,PubMed,and SwissTargetPrediction databases,the active ingredients and targets of N.officinalis were searched.At the same time,the targets of diabetic nephropathy were obtained in GeneCards and Disgenet databases.After the intersection was imported into the String da-tabase,the core targets were screened,and the targets were enriched and analyzed.Molecular docking verification,and cell experi-ments verified the effective protective effect of N.officinalis on diabetic nephropathy.Results:A total of 9 effective components,258 corresponding targets and 5 333 disease targets were screened,and 132 common targets were obtained by intersection,mainly IL6,ALB,STAT3,PPARG,EGFR and other targets.Enrichment analysis showed that the signaling pathways of N.officinalis in the treatment of diabetic nephropathy mainly involved positive regulation of gene expression,cell solute,ATP binding,HIF-1,FoxO,PI3K-Akt and other pathways.Molecular docking showed that the active components of N.officinalis could spontaneously bind to the core protein.At the same time,the Hederagenin with the highest binding fraction was verified in vitro.The results showed that Hederagenin could protect high glucose-induced apoptosis,inhibit cell migration and increase cell proliferation rate.Conclusion:In this study,the components and mechanisms of N.officinalis in the treatment of diabetic nephropathy were studied by network pharmacology,and it was found that N.officinalis could play a therapeutic role through multi-target,multi-component and multi-pathway.Hederagenin contained in N.officinalis is likely to be the basis for its treatment of diabetic nephropathy.In vi-tro experiments have preliminarily verified that the active ingredient hederagenin in N.officinalis can alleviate cell damage induced by high glucose and increase cell proliferation rate,which provides a new idea for the treatment of diabetic nephropathy by Li medi-cine N.officinalis.关键词
胆木/网络药理学/糖尿病肾病Key words
Nauclea officinalis/Network pharmacology/Diabetic nephropathy分类
医药卫生引用本文复制引用
张瀚铭,杨月华,霍天祺,刘颖,吴珠,杨卫丽..黎药胆木治疗糖尿病肾病的网络药理学研究及实验验证[J].海南医科大学学报,2025,31(18):1361-1369,9.基金项目
This study was supported by Natural Science Foundation of Hainan Province(823MS147) （823MS147）
Hainan Natural Science Foundation High Level Talent Project(820RC624) 海南省自然科学基金(823MS147) （820RC624）
海南省自然科学基金高层次人才项目(820RC624) （820RC624）
